Claudia Graham, PhD, MPH, Dexcom, Inc., San Diego, CA
Claudia Graham Senior Vice President – Global Access Claudia Graham is Senior Vice President, Global Access at Dexcom, Inc... Since joining Dexcom as Vice President of Marketing in 2008, Claudia has been instrumental in the successful launches of the Seven Plus and the G4 PLATINUM CGM systems. Globally recognized as a thought leader in access to diabetes technologies, Claudia became Vice President of Global Access in early 2013. In this role, she has navigated the complexities of the healthcare system and health economics to define a strategy for reimbursement and has made significant inroads to improving access to CGM for patients and physicians both domestically and internationally through successful government relations, health economics and outcomes work, and advocacy initiatives. Prior to Dexcom, she was Vice President of Marketing & Product Development at MiniMed, and subsequently served as Vice President of Global Access Therapy at Medtronic MiniMed. Before working in the medical device sector, she was a Director of Marketing for Warner Lambert (Parke-Davis). Claudia has also been a member of various national and local advisory boards serving the medical community, including the national board of the Medical Marketing Association of America, The College Diabetes Network, the community board of directors for the Northridge Hospital Medical Center and the San Diego and Los Angeles chapters of the Juvenile Diabetes Research Foundation. She has been professionally active in the diabetes community for many years, having published and presented numerous articles at scientific conferences of the ADA, EASD and others. She received her bachelor’s degree and her PhD from the University of Southern California. In addition she received her Masters of Public Health from the University of California, Los Angeles.
William Henry Ludlam, MD, PhD, Chiasma, Inc., Newton,
William “Bill” Ludlam currently serves as Vice President, Medical Affairs, Chiasma Pharmaceutical Company in Newton, MA. Bill has committed his career to the discovery and implementation of novel treatment options for patients. He obtained both his MD and PhD (Developmental Neuroscience, Advisor: John A. “Jack” Kessler) degrees at the Albert Einstein College of Medicine and did his Internal Medicine Residency and Endocrinology Fellowship (Chairman: D. Lynn Loriaux) training at the Oregon Health & Sciences University (OHSU). Bill continued his basic science training with an NIH K08 Career development award at the Vollum Institute with Richard H. “Dick” Goodman studying the histone acetylation and chromatin remodeling functions of CBP, the first discovered co-activator of transcription. In 2002, Bill entered the clinical portion of his career and over the next decade developed two different pituitary diseases treatment centers -- in Portland, OR and Seattle, WA. During this time he was very active in treating pituitary patients (particularly Cushing’s disease and Acromegaly) from around the US as well as other countries and headed a clinical research program looking at novel treatment options for pituitary disorders. In 2012 he joined Novartis Pharmaceuticals Corporation and in 2015 made the transition to Chiasma to head their Medical Affairs program. Throughout his career, Bill has been an active researcher, speaker, served on many national committees and has published over 100 papers and abstracts.
Sethu Reddy, MD, MBA, Joslin Diabetes Center, Chestnut Hill, MA
Dr. Sethu Reddy is past-Chief of Adult Diabetes at Joslin Diabetes Center, Harvard, in Boston. He is past-Chairman of Endocrinology, Diabetes & Metabolism at Cleveland Clinic, currently ranked 2nd in the US by US News & World and most recently was VP for Medical Affairs at Merck. He was a key sponsor of Merck's adherence initiative and was the Lead for Medical Solutions as part of the Global Customer Centricity initiative at Merck. He has consistently supported continuing education in academia and pharma. Dr. Reddy has been actively involved in numerous clinically relevant projects with Endocrine Society and AACE since 1996 and is currently on the Board of Trustees for the American College of Endocrinology. In 2007, he received the distinction of Mastership in the American College of Endocrinology.
Curtis Carter, AstraZeneca, San Diego, CA
WHL: Employee, Chiasma, Ltd. SR: Speaker, Merck & Co.. Disclosure Not Provided: CG, CC
After this session, attendees will be able to:
- Have a clear idea of the career paths open to clinicians and scientists in private industry.
- Understand the differences between large and small pharmaceutical companies.
- Understand the roles that an MD clinician and MD or PhD scientist will have in these settings.
- Understand the general career trajectory from new hire to management.
- Be aware of the typical compensation ranges.
- Understand the scientific and management culture in private industry and compare the differences with academia or private practice.